EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 15th, 2023 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of August, 2020 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason S. Baum (hereinafter, the “Executive”).
SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 15th, 2023 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Second Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 3rd day of April, 2023 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and John Mark O’Mahony (hereinafter, the “Executive”).
STRATEGIC PARTNERSHIP AND LICENSE AGREEMENTPartnership and License Agreement • May 15th, 2023 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
This STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT (this “Agreement”) is made as of August 13, 2021 (the “Effective Date”), by and between NOVAROCK BIOTHERAPEUTICS LTD., a Delaware corporation (“NovaRock”), having a place of business at 801 Charles Ewing Blvd, Ewing, NJ 08628, USA, and FLAME BIOSCIENCES, INC., a Delaware corporation (“Flame”), having a place of business at 280 Union Square Drive, New Hope, PA 18938. NovaRock and Flame are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENTCollaboration Agreement • May 15th, 2023 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS COLLABORATION AGREEMENT (the “Agreement”) is made effective as of August 10, 2020 (the “Effective Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Flame Biosciences, Inc., 555 Madison Ave., Suite 1201, New York, NY 10022 (“Flame”).
ContractLeap Therapeutics, Inc. • May 15th, 2023 • Pharmaceutical preparations • New York
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH TRANSACTION UNDER APPLICABLE SECURITIES LAWS OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
